NJ Bio Inc. and Charles River Laboratories Inc. have entered a strategic alliance to offer complementary services to clients including early development and optimization to manufacturing of antibody-drug conjugates (ADCs).

 
Charles River provides antibody development and preclinical evaluation of ADCs. The company’s antibody, oncology, immunology and safety assessment services support ADC programs from proof-of-concept to clinical candidates.
 
NJ Bio Inc. specializes in providing integrated chemistry and bioconjugation services, with expertise in the synthesis and GMP manufacturing of payloads, linkers, linker-payloads, ADCs, TPDs, and oligo-conjugates, and non-oncology related conjugations. NJ Bio supports early phase discovery, proof-of-concept, process and analytical development, manufacture of preclinical batches, and manufacture and release of linkers, payloads, linker-payloads, and ADCs form its GMP facility.